NCT04813796已完成1 期
A Phase 1, Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18-55 Years
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 104
- 试验地点
- 10
- 主要终点
- Number of Participants with Unsolicited Adverse Events (AEs)
研究概览
简要总结
The primary goal for this study is to evaluate the safety and reactogenicity of 3 dose levels of mRNA-1283 and 1 dose level of mRNA-1273 vaccine given to healthy adults in 2 doses, 28 days apart, and 1 dose level of mRNA-1283 administered as a single dose to healthy adults.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
盲法说明
Participants who are offered an opportunity to receive an additional injection of mRNA-1273, will participate in an open-label part of the study.
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Understands and agrees to comply with the study procedures and provides written informed consent.
- •According to the assessment of the investigator, is in good general health and can comply with study procedures.
- •Body mass index (BMI) of 18 kilograms/square meter (kg/m^2) to 35 kg/m^2 (inclusive) at the Screening Visit (Day 0).
- •For female participants of childbearing potential: negative pregnancy test, adequate contraception or has abstained from all activities that could result in pregnancy for at least 28 days prior to the first injection, agreement to continue adequate contraception or abstinence through 3 months following the second injection, and not currently breastfeeding.
排除标准
- •Known history of SARS-CoV-2 infection or known exposure to someone with SARS-CoV-2 infection or COVID-19 in the past 30 days.
- •Positive serology results for SARS-CoV-2 at the Screening Visit. A negative serological test for SARS-CoV-2, performed on a blood sample obtained at the Screening Visit, is required before a participant can be dosed.
- •Travel outside of the United States in the 28 days prior to the Screening Visit (Day 0).
- •Prior administration of an investigational, authorized, or licensed CoV (for example, SARS-CoV-2, SARS-CoV, or Middle East Respiratory Syndrome [MERS]-CoV) vaccine, based on medical history interview.
- •Current treatment with investigational agents for prophylaxis against COVID-
- •Recent (within the last 12 months) use of a dermal filler.
- •Has a medical, psychiatric, or occupational condition that may pose additional risk as a result of participation or that could interfere with safety assessments or interpretation of results according to the investigator's judgment.
- •Has received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for corticosteroids, 10 milligrams (mg)/day of prednisone equivalent) or is anticipating the need for immunosuppressive treatment at any time during participation in the study.
- •Has received or plans to receive any licensed vaccine 28 days prior to the first injection (Day 1) or plans to receive a licensed vaccine within 28 days before or after any study injection, with the exception of licensed influenza vaccines, which may be received more than 14 days before the first study injection or more than 14 days after the second study injection.
- •Receipt of systemic immunoglobulins or blood products within 3 months prior to the Screening Visit (Day 0) or plans for receipt during the study.
- •Current use of any inhaled substance (for example, tobacco or cannabis smoke, nicotine vapors).
- •History of chronic smoking (1 cigarette a day) within 1 year of the Screening Visit.
- •Resides in a nursing home.
- •Has donated 450 milliliters (mL) of blood products within 28 days prior to the Screening Visit or plans to donate blood products during the study.
- •Participated in an interventional clinical study within 28 days prior to the Screening Visit based on the medical history interview or plans to do so while participating in this study.
结局指标
主要结局
Number of Participants with Unsolicited Adverse Events (AEs)
时间窗: Up to Day 57 (28 days after second dose)
Number of Participants with Medically-Attended AEs (MAAEs), AE of Special Interest (AESIs), and Serious Adverse Events (SAEs)
时间窗: Up to Day 394 (1 year after second dose)
Number of Participants with Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs)
时间窗: Up to Day 36 (7 days after second dose)
次要结局
- Geometric Mean (GM) of SARS-CoV-2 Specific Neutralizing Antibody (nAb)(Day 1, Day 29, Day 36, Day 57, Day 209, and Day 394)
- Seroconversion as Measured by an Increase of SARS-CoV-2-Specific nAb Titer or bAb Titer(Day 1, Day 29, Day 36, Day 57, Day 209, and Day 394)
- GM of SARS-CoV-2-Specific Binding Antibody (bAb)(Day 1, Day 29, Day 36, Day 57, Day 209, and Day 394)
研究者
研究点 (10)
Loading locations...
相似试验
进行中（未招募）
1 期
Safety and Immunogenicity of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 18 Years and AboveHerpes ZosterNCT05636436MAXVAX Biotechnology Limited Liability Company132
进行中（未招募）
1 期
A Phase 1 Study to Evaluate JCXH-108, an mRNA-based Vaccine Against RSVRespiratory Syncytial Virus (RSV)Infectious DiseaseNCT06564194Immorna Biotherapeutics, Inc.75
已完成
1 期
Safety and Immunogenicity of IVX-A12 in Healthy Older AdultsHealthyNCT05664334Icosavax, Inc.140
已完成
2 期
A Study to Assess the Safety, Reactogenicity and Immunogenicity of a Trivalent Inactivated Poliovirus Vaccine (IPV) Based on Sabin Strains Compared to Conventional Salk IPV in a 6, 10 and 14 Weeks of Age Immunization ScheduleHealthyNCT03566940Janssen Vaccines & Prevention B.V.302
已完成
1 期
Dose Ranging Study to Evaluate Immunogenicity and Safety of Adjuvanted or Non-adjuvanted Cell Culture-derived H5N1 Influenza Vaccine in Young Adults (18-40 Years Old)InfluenzaNCT00812019Seqirus753